Friday, January 19, 2018, San Francisco, California, 7:00 PM – 8:30 PM (Pacific Time)

Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Hepatocellular Carcinoma

Location:
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Time:
6:30 PM – 7:00 PM (Pacific Time) — Registration and Buffet Dinner
7:00 PM – 8:30 PM (Pacific Time) — Educational Meeting

Meeting Room:
Yerba Buena Ballroom, Salon 1-7 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Ghassan Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Josep M Llovet, MD, PhD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Professor of Research — ICREA
Director, Master in Translational Medicine
BCLC Group, Liver Unit
CIBERehd, IDIBAPS
Hospital Clínic de Barcelona
University of Barcelona
Barcelona, Spain

Andrew X Zhu, MD, PhD 
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Additional faculty to be announced

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2018 Gastrointestinal Cancers Symposium.

6:30 PM – 7:00 PM (Pacific Time) — Registration and Buffet Dinner
7:00 PM – 8:30 PM (Pacific Time) — Educational Meeting

Overview
Four investigators specializing in the management of hepatocellular carcinoma (HCC) will serve as the faculty, and Research To Practice (RTP) president and medical oncologist Dr Neil Love will moderate the symposium. Prior to the meeting, RTP will recruit 21 additional HCC investigators who, along with the faculty, will participate in a unique educational assessment designed to document practice patterns for an array of common and less frequently encountered clinical scenarios. Key data points from this assessment will be used to formulate the program agenda. Each module will feature a faculty member-led review of emerging and ongoing research and a corresponding panel discussion related to the presentation and relevant data from the premeeting survey. Clinician attendees will use iPads® to complete a similar survey, and the results from both cohorts will be juxtaposed throughout the event to foster additional discussion and debate.

Detailed agenda to be announced by mid-December.

Topics for Discussion

MODULE 1: Existing and Emerging Pharmacologic Options for Patients with Newly Diagnosed Unresectable HCC

MODULE 2: Selection and Sequencing of FDA-Approved Therapies for Patients with Previously Treated Advanced HCC

MODULE 3: Promising Investigational Therapies in HCC

MODULE 4: Multidisciplinary Management of Localized and Locally Advanced Disease

Target Audience:
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma (HCC).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Develop evidence-based strategies to properly diagnose and stage HCC, and use this information to counsel patients regarding their long-term prognosis.
  • Recognize clinical indications for the use of surgical and nonsurgical local treatment modalities in HCC, and appreciate the risks and benefits associated with these approaches.
  • Consider age, performance status, liver function and other clinical and logistical factors in the selection and sequencing of available systemic agents for patients with unresectable or metastatic HCC.
  • Develop an understanding of the biologic rationale for and available clinical data with anti-PD-1/PD-L1 antibodies in the treatment of HCC.
  • Appraise available Phase III data with and consider the potential clinical role of cabozantinib after failure of treatment with sorafenib.
  • Counsel patients regarding the incidence and manifestation of side effects and toxicities associated with existing and emerging targeted agents and immunotherapeutic approaches used in the management of advanced HCC.
  • Recall available and emerging data with other investigational agents currently in clinical testing for HCC and, as applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals and Exelixis Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room:
Yerba Buena Ballroom, Salon 1-7 (Lower B2 Level)

Directions:
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2018 Gastrointestinal Cancers Symposium is taking place.

 

This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, nurse, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.